Acivicin with glutaminase regulates proliferation and invasion of human MCF-7 and OAW-42 cells-An in vitro study

Indian Journal of Experimental Biology

Volumn 46, Issue 1, 2008, Pages 22-26

  Roy, Subhadra ^a   Ghosh, Sonali ^a   Mallick, Palash ^a   Maity, Putul ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

Author keywords

Acivicin; Glutaminase; Invasion; MCF 7; OAW 42; Proliferation

Indexed keywords

ESCHERICHIA COLI;

ACIVICIN; ANTINEOPLASTIC ANTIMETABOLITE; COLLAGEN; GELATINASE B; GLUTAMINASE; GLUTAMINE; ISOXAZOLE DERIVATIVE; LAMININ; MATRIGEL; PROTEOGLYCAN; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; VASCULOTROPIN A;

ARTICLE; BREAST TUMOR; CANCER INVASION; CELL PROLIFERATION; CHEMISTRY; DRUG COMBINATION; FEMALE; HUMAN; IN VITRO STUDY; METABOLISM; OVARY TUMOR; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COLLAGEN; DRUG COMBINATIONS; FEMALE; GLUTAMINASE; GLUTAMINE; HUMANS; ISOXAZOLES; LAMININ; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PROTEOGLYCANS; TETRAZOLIUM SALTS; THIAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 50649114905     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Reitzer L J, Wice B M & Kennell D, Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells, J Biol Chem, 254 (1979) 2669.
2. Spittler A, Oehler R, Goetzinger P, Holzer S, Reissner C M, Leutmezer F, Rath V, Wrba F, Fuegger R, Boltz-Nitulescu G & Roth E, Low glutamine concentrations induce phenotypical and functional differentiation of U937 myelomonocytic cells, J Nutr, 127 (1997) 2151.
3. Dvorak H F, Harvey V S, Estrella P, Brown L F, McDonagh J & Dvorak A M, Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing, Lab Invest, 57 (1987) 673.
4. Poster D S, Bruno S, Penta J, Neil G L & McGovern J P, Acivicin. An antitumor antibiotic, Can Clin Trials, 4 (1981) 327.
5. Houchens D P, Ovejera A A, Sheridan M A, Johnson R K, Bogden A E & Neil G L, Therapy for mouse tumors and human tumor xenografts with the antitumor antibiotic AT-125 (NSC-163501), Cancer Treat Rep, 63 (1979) 473.
6. Falkson G, Cnaan A, Simson I W, Dayal Y, Falkson H, Smith T J & Haller D G, A randomized phase II study of acivicin and 4′deoxydoxorubicin in patients with hepatocellular carcinoma in an Eastern Cooperative Oncology Group study, Am J Clin Oncol, 13 (1990) 510.
7. Smulski D R, Huang L L, McCluskey M P, Reeve M J, Vollmer A C, Van Dyk T K & LaRossa R A, Combined, functional genomic-biochemical approach to intermediary metabolism: interaction of acivicin, a glutamine amidotransferase inhibitor, with Escherichia coli K-12, J Bacteriol, 183 (2001) 3353.
8. Rosenfeld H & Roberts J, Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase, Cancer Res, 41 (1981) 1324.
9. Holcenberg J S, Enhanced effect of an L-Glutamine antagonist, L-(alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro- 5-isoxazoleacetic acid, by Acinetobacter L-glutaminase-Lasparaginase, Cancer Treat Rep, 63 (1979) 1109.
10. Roberts J, Holcenberg J S & Dolowy W C, Glutaminase induced prolonged regression of established Ehrlich carcinoma, Life Sci, II 10 (1971) 251.
11. Colquhoun A & Newsholme E A, Aspects of glutamine metabolism in tumour cells, Biochem Mol Biol Int, 41 (1997) 583.
12. Bobrovnikova-Marjon E V, Marjon P L, Barbash O, Vander Jagt D L & Abcouwer S F, Expression of angiogenic factors vascular endothelial growth factors and Interleukin- 8/CXCL8 is highly responsive to ambient glutamine availability; role of nuclear factor-kappaB and activating protein-1, Cancer Res, 64 (2004) 4858.
13. Roy S & Maity P, Effect of glutamine analogue- acivicin on tumor induced angiogenesis in Ehrlich ascites carcinoma, Indian J Exp Biol, 43 (2005) 407.
14. Shi H R, Song W J, Chen Z M & Wu Q H, Expression and clinical significance of endostatin and vascular endothelial growth factor in ovarian carcinoma, Ai Zheng, 24 (2005) 1127.
15. Sledge G W Jr, Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects, Semin Oncol, 29 (2002) 104.
16. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z & Hanahan D, Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis, Nat Cell Biol, 2 (2000) 737.
17. Mira E, Lacalle R A, Buesa J M, de Buitrago G G, Jimenez- Baranda S, Gomez-Mouton C, Martinez-A C & Manes S, Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface, J Cell Sci, 117 (2004) 1847.
18. Ghosh S, Roy S, Banerjee M & Maity P, Modulation of tumor induced angiogenesis in Ehrlich ascites tumor, J Exp Clin. Cancer Res, 23 (2004) 681.
19. Hanka L J, Martin D G & Neil G L, A new antitumor antimetabolite, (alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro- 5-isoxazoleacetic acid (NSC-163501): antimicrobial reversal studies and preliminary evaluation against L1210 mouse leukemia in vivo, Cancer Chemother Rep, 57 (1973) 141.
20. Neil G L, Berger A E, Bhuyan B K, Blowers C L & Kuentzel S L, Studies of the biochemical pharmacology of the fermentation-derived antitumor agent, (alpha S, 5S)- alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid AT-125, Adv Enzyme Regul, 17 (1978) 375.